5536-17-4
Chemical Structure
Vidarabine
Synonym(s): Ara-A; Adenine Arabinoside; 9-β-D-Arabinofuranosyladenine
- CAS No.: 5536-17-4
- Formula:C10H13N5O4
- Molecular Weight:267.25
IUPAC Name: (2R,3S,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
InChIKey: OIRDTQYFTABQOQ-UHTZMRCNSA-N
SMILES: OC[C@@H]1[C@@H](O)[C@H](O)[C@H](N2C3=NC=NC(N)=C3N=C2)O1
Biological Activity: Vidarabine (Ara-A) is a Purine nucleoside derivative and Antiviral agent. The triphosphate derivative of Vidarabine competitively inhibits DNA polymerase, incorporates into the terminus of elongating DNA molecules, and interferes with the early steps of viral DNA synthesis. Vidarabine inhibits the replication of herpes simplex virus, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus and vaccinia virus, reduces viral shedding, and accelerates skin healing. Vidarabine is metabolized to arabinosyl hypoxanthine, causes minimal impairment of corneal wound healing in rabbit models, and is associated with recurrence of herpes simplex encephalitis. Vidarabine can be used in the research of herpetic keratoconjunctivitis, herpes simplex encephalitis, herpetic uveitis, and chronic active hepatitis associated with hepatitis B virus[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vidarabine | 98.85% | Vidarabine (Ara-A) is a Purine nucleoside derivative and Antiviral agent. The triphosphate derivative of Vidarabine competitively inhibits DNA polymerase, incorporates into the terminus of elongating DNA molecules, and interferes with the early steps of viral DNA synthesis. Vidarabine inhibits the replication of herpes simplex virus, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus and vaccinia virus, reduces viral shedding, and accelerates skin healing. Vidarabine is metabolized to arabinosyl hypoxanthine, causes minimal impairment of corneal wound healing in rabbit models, and is associated with recurrence of herpes simplex encephalitis. Vidarabine can be used in the research of herpetic keratoconjunctivitis, herpes simplex encephalitis, herpetic uveitis, and chronic active hepatitis associated with hepatitis B virus. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Vidarabine (Standard) | ≥98% | Vidarabine (Standard) (Ara-A (Standard)) is the analytical standard of Vidarabine (HY-B0277). This product is intended for research and analytical applications. Vidarabine (Ara-A) is a Purine nucleoside derivative and Antiviral agent. The triphosphate derivative of Vidarabine competitively inhibits DNA polymerase, incorporates into the terminus of elongating DNA molecules, and interferes with the early steps of viral DNA synthesis. Vidarabine inhibits the replication of herpes simplex virus, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus and vaccinia virus, reduces viral shedding, and accelerates skin healing. Vidarabine is metabolized to arabinosyl hypoxanthine, causes minimal impairment of corneal wound healing in rabbit models, and is associated with recurrence of herpes simplex encephalitis. Vidarabine can be used in the research of herpetic keratoconjunctivitis, herpes simplex encephalitis, herpetic uveitis, and chronic active hepatitis associated with hepatitis B virus. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Whitley R, et al. Vidarabine: a preliminary review of its pharmacological properties and therapeutic use. Drugs. 1980 Oct;20(4):267-82. [Content Brief]
- [2]. VanLandingham KE, et al. Relapse of herpes simplex encephalitis after conventional acyclovir therapy. JAMA. 1988;259(7):1051-1053. [Content Brief]
- [3]. Stolk LM, et al. Formulation of a stable vidarabine infusion fluid. Pharm Weekbl Sci. 1983;5(2):57-60. [Content Brief]
